NextPlat 2025 Q3 Earnings 71.5% Net Loss Reduction Amid Revenue Decline

NextPlat (NXPL), a global healthcare and e-commerce technology company, reported its fiscal 2025 Q3 earnings on Nov 14, 2025. The company narrowed losses to $0.08 per share, a 63.6% improvement year-over-year, and reduced its net loss by 71.5% to $2.19 million. Despite these gains, revenue fell 10.5% to $13.75 million, reflecting challenges in its healthcare segment.

Revenue

Total revenue for NextPlat in Q3 2025 declined by 10.5% to $13.75 million, down from $15.37 million in the same period last year. The E-Commerce Operations segment contributed $3.70 million, while the Healthcare Operations segment accounted for $10.05 million of the total revenue.

Earnings/Net Income

NextPlat’s net loss narrowed to $2.19 million in Q3 2025, a 71.5% reduction from $7.66 million in the prior year. The EPS improved to -$0.08 per share, up from -$0.22 per share in 2024 Q3. The EPS improvement of 63.6% to -$0.08 per share highlights progress in narrowing losses, though the company remains unprofitable.

Post-Earnings Price Action Review

The stock price of NextPlat plummeted 11.72% during the latest trading day, 16.76% over the past week, and 15.89% month-to-date, reflecting investor skepticism. A backtest of a strategy to buy shares on the earnings date and hold for 30 days showed moderate returns: a 25.44% gain over three years with a CAGR of 8.16%. The peak gain of 31.82% occurred in the first year, followed by a more modest performance. While the strategy demonstrated resilience, its lack of aggressive growth may deter high-risk seekers. Historical data does not guarantee future performance, and investors must consider evolving market conditions and company developments.

CEO Commentary

CEO David Phipps acknowledged Q3 as the “low point in our business,” emphasizing that cost-cutting and efficiency measures have begun to reverse sequential declines. He highlighted reduced operating expenses by nearly 40% and improved prescription volumes in the healthcare segment. The company remains focused on achieving operational break-even by H2 2026 through strategic investments in sales and business development.

Guidance

NextPlat aims to achieve operational break-even in the second half of 2026 and anticipates sequential improvements in Q4 2025 and beyond. Management expects expanded healthcare prescription volumes and cost-reduction benefits to drive performance.

Additional News

1. Cost-Cutting Initiatives: The company reduced annualized overhead expenses by $2.1 million through staff reductions and operational streamlining.

2. New Product Launch: NextPlat launched nutraceutical products in the UK and EU, preparing for an AI-driven marketing campaign.

3. Leadership Changes: The company appointed a new CEO and Chairman as part of a strategic refocus on healthcare and e-commerce growth.